We O
compared O
the O
toxicity O
of O
NS O
- O
718 O
with O
that O
of O
Fungizone B
( O
amphotericin B
B I
- I
sodium I
deoxycholate I
; O
D B
- I
AmB I
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin B
B I
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

Toleration O
of O
high O
doses O
of O
angiotensin B
- I
converting I
enzyme I
inhibitors I
in O
patients O
with O
chronic O
heart O
failure O
: O
results O
from O
the O
ATLAS O
trial O
. O

METHODS O
: O
Eighty O
- O
eight O
patients O
with O
chronic O
hepatitis O
C O
who O
received O
interferon B
- I
alpha I
- I
2b I
at O
a O
dose O
of O
6 O
MU O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin B
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

However O
, O
the O
patient O
tolerated O
well O
an O
alternative O
reverse O
transcriptase O
inhibitor O
, O
2 B
' I
3 I
' I
dideoxyinosine I
. O

Motor O
impairment O
, O
dopamine B
( O
DA B
) O
neuronal O
activity O
and O
proenkephalin B
( O
PENK B
) O
gene O
expression O
in O
the O
caudate O
- O
putamen O
( O
CPu O
) O
were O
measured O
in O
6 B
- I
OHDA I
- O
lesioned O
and O
treated O
( O
L B
- I
DOPA I
+ I
benserazide I
) O
CB1 O
KO O
and O
WT O
mice O
. O

Treatment O
with O
L B
- I
DOPA I
+ I
benserazide I
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias O
in O
CB1 O
KO O
than O
in O
WT O
mice O
. O

Depression O
, O
impulsiveness O
, O
sleep O
, O
and O
memory O
in O
past O
and O
present O
polydrug O
users O
of O
3 B
, I
4 I
- I
methylenedioxymethamphetamine I
( O
MDMA B
, O
ecstasy B
) O
. O

RATIONALE O
: O
Ecstasy B
( O
3 B
, I
4 I
- I
methylenedioxymethamphetamine I
, O
MDMA B
) O
is O
a O
worldwide O
recreational O
drug O
of O
abuse O
. O

All B
- I
trans I
retinoic I
acid I
- O
induced O
inflammatory O
myositis O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
. O

All B
- I
trans I
retinoic I
acid I
( O
ATRA B
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

1 B
, I
3 I
- I
Butadiene I
, O
CML O
and O
the O
t O
( O
9 O
: O
22 O
) O
translocation O
: O
A O
reality O
check O
. O

UNASSIGNED O
: O
Epidemiological O
studies O
of O
1 B
, I
3 I
- I
butadiene I
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

We O
have O
proposed O
that O
1 B
, I
3 I
- I
butadiene I
metabolites O
be O
so O
tested O
as O
a O
reality O
check O
on O
the O
epidemiological O
reports O
. O

Conditions O
that O
will O
be O
required O
for O
studies O
of O
1 B
, I
3 I
- I
butadiene I
are O
discussed O
. O

Etoposide B
( O
VP B
- I
16 I
- I
213 I
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors O
and O
hematologic O
malignancies O
. O

Differential O
effects O
of O
1 B
, I
4 I
- I
dihydropyridine I
calcium B
channel I
blockers I
: O
therapeutic O
implications O
. O

Furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 B
- I
HT I
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 B
, I
7 I
- I
dihydroxytryptamine I
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac O
responses O
to O
clonidine B
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

Susceptibility O
to O
seizures O
produced O
by O
pilocarpine B
in O
rats O
after O
microinjection O
of O
isoniazid B
or O
gamma B
- I
vinyl I
- I
GABA I
into O
the O
substantia O
nigra O
. O

Application O
of O
an O
irreversible O
inhibitor O
of O
GABA B
transaminase O
, O
gamma B
- I
vinyl I
- I
GABA I
( O
D B
, I
L I
- I
4 I
- I
amino I
- I
hex I
- I
5 I
- I
enoic I
acid I
) O
, O
5 O
micrograms O
, O
into O
the O
SNR O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures O
produced O
by O
pilocarpine B
, O
380 O
mg O
/ O
kg O
. O

Microinjections O
of O
gamma B
- I
vinyl I
- I
GABA I
, O
5 O
micrograms O
, O
into O
the O
dorsal O
striatum O
, O
bilaterally O
, O
failed O
to O
prevent O
the O
development O
of O
convulsions O
produced O
by O
pilocarpine B
, O
380 O
mg O
/ O
kg O
. O

Increased O
frequency O
and O
severity O
of O
angio O
- O
oedema O
related O
to O
long O
- O
term O
therapy O
with O
angiotensin B
- I
converting I
enzyme I
inhibitor I
in O
two O
patients O
. O

Pharmacological O
studies O
on O
a O
new O
dihydrothienopyridine B
calcium I
antagonist O
, O
S B
- I
312 I
- I
d I
. O

S B
- I
312 I
, O
S B
- I
312 I
- I
d I
, O
but O
not O
S B
- I
312 I
- I
l I
, O
L O
- O
type O
calcium B
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic O
tonic O
convulsions O
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine B
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

S B
- I
312 I
, O
S B
- I
312 I
- I
d I
, O
but O
not O
S B
- I
312 I
- I
l I
, O
L O
- O
type O
calcium B
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic O
tonic O
convulsions O
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine B
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

Although O
moderate O
anticonvulsant O
effects O
of O
S B
- I
312 I
- I
d I
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions O
induced O
by O
pentylenetetrazole B
( O
85 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
or O
bemegride B
( O
40 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
no O
effects O
were O
observed O
in O
convulsions O
induced O
by O
N B
- I
methyl I
- I
D I
- I
aspartate I
, O
picrotoxin B
, O
or O
electroshock O
in O
Slc O
: O
ddY O
mice O
. O

S B
- I
312 I
- I
d I
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy O
. O

We O
investigated O
the O
effects O
of O
clentiazem B
, O
a O
1 B
, I
5 I
- I
benzothiazepine I
calcium B
antagonist O
, O
on O
epinephrine B
- O
induced O
cardiomyopathy O
in O
rats O
. O

Analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow O
- O
up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
TFL O
: O
nine O
cycles O
( O
5 O
% O
) O
were O
associated O
with O
grade O
3 O
/ O
4 O
neutropenia O
requiring O
hospitalization O
; O
seven O
( O
4 O
% O
) O
cycles O
in O
two O
patients O
required O
granulocyte B
colony I
- I
stimulating I
factor I
due O
to O
neutropenia O
; O
no O
patient O
required O
platelet O
transfusions O
. O

Efficacy O
and O
proarrhythmia O
with O
the O
use O
of O
d B
, I
l I
- I
sotalol I
for O
sustained O
ventricular O
tachyarrhythmias O
. O

This O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades O
de O
pointes O
, O
and O
the O
presumable O
risk O
factors O
for O
torsades O
de O
pointes O
in O
patients O
treated O
with O
d B
, I
l I
- I
sotalol I
for O
sustained O
ventricular O
tachyarrhythmias O
. O

Eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary O
artery O
disease O
, O
and O
20 O
with O
dilated O
cardiomyopathy O
) O
with O
inducible O
sustained O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
received O
oral O
d B
, I
l I
- I
sotalol I
to O
prevent O
induction O
of O
the O
ventricular O
tachyarrhythmia O
. O

During O
oral O
loading O
with O
d B
, I
l I
- I
sotalol I
, O
continuous O
electrocardiographic O
( O
ECG O
) O
monitoring O
was O
performed O
. O

Those O
patients O
in O
whom O
d B
, I
l I
- I
sotalol I
prevented O
induction O
of O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

Induction O
of O
the O
ventricular O
tachyarrhythmia O
was O
prevented O
by O
oral O
d B
, I
l I
- I
sotalol I
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular O
tachyarrhythmia O
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O
5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d B
, I
l I
- I
sotalol I
once O
daily O
. O

Induction O
of O
the O
ventricular O
tachyarrhythmia O
was O
prevented O
by O
oral O
d B
, I
l I
- I
sotalol I
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular O
tachyarrhythmia O
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O
5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d B
, I
l I
- I
sotalol I
once O
daily O
. O

Four O
( O
5 O
% O
) O
patients O
had O
from O
torsades O
de O
pointes O
during O
the O
initial O
oral O
treatment O
with O
d B
, I
l I
- I
sotalol I
. O

However O
, O
the O
oral O
dose O
of O
d B
, I
l I
- I
sotalol I
was O
significantly O
lower O
in O
patients O
with O
torsades O
de O
pointes O
( O
200 O
+ O
/ O
- O
46 O
vs O
. O
328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O
0017 O
) O
. O

One O
female O
patient O
with O
stable O
cardiac O
disease O
had O
recurrent O
torsades O
de O
pointes O
after O
2 O
years O
of O
successful O
treatment O
with O
d B
, I
l I
- I
sotalol I
. O

Torsades O
de O
pointes O
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d B
, I
l I
- I
sotalol I
. O

Pronounced O
changes O
in O
the O
surface O
ECG O
( O
cycle O
length O
, O
QT O
, O
and O
QTc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d B
, I
l I
- I
sotalol I
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades O
de O
pointes O
. O

Other O
ECG O
parameters O
before O
the O
application O
of O
d B
, I
l I
- I
sotalol I
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades O
de O
pointes O
. O

Therefore O
programmed O
electrical O
stimulation O
in O
the O
case O
of O
d B
, I
l I
- I
sotalol I
seems O
to O
be O
of O
limited O
prognostic O
value O
. O

